• Source: Scopus
  • Calculated based on number of publications stored in Pure and citations from Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile


Dr. Ole Tietz is a Research Fellow at the Dementia Research Centre of the Faculty of Medicine and Health Sciences at Macquarie University. Ole graduated from Imperial College London, UK, and completed his PhD at the University of Alberta, Canada, in 2015. His thesis dealt with the imaging of inflammation using radiotracers directed against cyclooxygenase-2 and was supervised by Prof. Frank Wuest. This was followed by post-doctoral fellowships at the University of Cambridge, where he developed imaging agents for early markers of neurodegeneration, and the University of Oxford, where he worked on technologies for transporting antibodies into cells. Ole is a member of the drug development group and works on developing antibodies for the treatment of dementia.

Research interests

Ole is interested in developing novel drugs against intracellular molecular targets for diagnosis and therapy of neurodegenerative diseases. This includes the rational design of small molecules and their optimization for cellular entry; the design and study of novel cell penetrating peptide complexes for the transport of exogenous cargo into cells; and the engineering and modification of antibodies to affect their endosomal escape and target engagement in the cytosol and nucleus.

Education/Academic qualification

Oncology, PhD, University of Alberta

6 Jan 201118 Nov 2015

Award Date: 18 Nov 2015

Biomedical Physical Chemistry, MRes, Imperial College London

5 Oct 200815 Dec 2009

Award Date: 12 Oct 2010

Chemistry, BSc

3 Oct 200525 Jun 2008

Award Date: 14 Oct 2008


Dive into the research topics where Ole Tietz is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles


Recent external collaboration on country/territory level. Dive into details by clicking on the dots or